section name header

Evidence summaries

Optimal Loading Dose of Warfarin for the Initiation of Oral Anticoagulation

There is insufficient evidence on the optimal loading dose of warfarin for the initiation of oral anticoagulation. Level of evidence: "D"

The quality of evidence is downgraded by study limitations (lack of/unclear allocation concealment and lack of blinding), by inconsistency (unexplained variability in results), and by imprecise results (few patients and wide confidence intervals).

Summary

A Cochrane review [Abstract] 1 included 4 studies with a total of 494 subjects to evaluate the efficacy of a 10-mg warfarin nomogram compared with a 5-mg warfarin nomogram among patients with venous thromboembolism (VTE). The proportion of participants who had achieved a therapeutic INR by day 5 was higher with 10-mg warfarin nomogram compared with 5-mg warfarin normogram (table T1), although there was substantial heterogeneity (I2 = 90%). A sensitivity analysis was performed using the random-effects model, and no difference was observed (RR 1.06, 95% CI 0.52 to 2.16). Each study was analyzed separately because it was not possible to perform a subgroup analysis. One study (n=201) showed significant benefit of a 10-mg warfarin nomogram for the proportion of outpatients with VTE who had achieved a therapeutic INR by day 5 (RR 1.78, 95% CI 1.41 to 2.25; NNTB = 3, 95% CI 2 to 4); another study (n=132) showed significant benefit of a 5-mg warfarin nomogram in outpatients with VTE (RR 0.58, 95% CI 0.36 to 0.93; NNTB = 5, 95% CI 3 to 28); the third study (n=50) showed no difference (RR 1.08, 95% CI 0.65 to 1.80). No difference was observed in recurrent venous thromboembolism, in major bleeding, or in minor bleeding (table T1).

10 mg warfarin initiation nomogram compared to 5 mg warfarin initiation nomogram for venous thromboembolism.

OutcomeParticipnats (studies)Assumed risk (5-mg warfarin nomogram)Corresponding risk (10-mg warfarin nomogram)RR (95% CI)
*fall in hemoglobin of > 20 g/L or transfusion of 2 or more units of red cells
Therapeutic INR383 (3)473 per 1000601 per 1000(497 to 729)1.27 (1.05 to 1.54)
Recurrent venous thromboembolism at 90 days312(2)17 per 100025 per 1000(7 to 95)1.48 (0.39 to 5.56)
Major bleeding at 14-90 days*494(4)17 per 100016 per 1000(4 to 58)0.97 (0.27 to 3.51)
Minor bleeding at 14-90 days243(2)50 per 100026 per 1000(8 to 92)0.52 (0.15 to 1.83)

Clinical comment: Acute thromboembolism is treated with LMWH together with warfarin dose titration. LMWH treatment is effective and safe, and thus there is no hurry with warfarin titration.

Another Cochrane review [Abstract] 2 included 12 studies with a total of 1 656 subjects. The studies assessed the effectiveness of different initiation doses of warfarin in several different situations.

5 mg versus 10 mg (4 studies, n=355): There was no clear benefit between 10 mg versus 5 mg loading dose (Table T2).

10 mg versus 5 mg for the initiation of oral anticoagulation

OutcomeParticipants (studies)Assumed risk (5 mg)Corresponding risk (10 mg)Relative risk (95% CI)
INR in-range by day 5352 (4)571 per 1000668 per 1000 (440 to 1000)1.17 (0.77 to 1.77)
INR in-range on day 5 (single INR measure)250 (2)504 per 1000751 per 1000 (509 to 1000)1.49 (1.01 to 2.21)
INR in-range by day 5 (2 consecutive INR measures)102 (2)714 per 1000614 per 1000 (443 to 850)0.86 (0.62 to 1.19)

5 mg versus other doses (2 studies, n=322): Heart valve replacement patients (INR target 1.5 to 2.6) receiving 2.5 mg compared to 5 mg took longer to achieve the therapeutic range (2.7 versus 2.0 days, P < 0.0001) but were less likely to have a supratherapeutic INR (26% versus 42%, P < 0.05). Another study compared 5 mg with a calculated dose that took account of age, weight, serum albumin and active malignancy. Patients receiving the calculated dose achieved the target range quicker (4.2 days versus 5 days, P = 0.007), although there was no difference in other end points.

Age-adjusted: Two studies (n=192) compared age adjusted doses to 10 mg initiation doses. More elderly patients receiving an age adjusted dose achieved a stable INR compared to those receiving a 10 mg initial dose. In both studies significantly fewer patients on the age adjusted regimens had high out-of-range INRs.

Genotype loading : 4 studies (n=701) used genotype guided dosing in one arm of each trial. Three studies reported no overall differences; the fourth study, which reported that the genotype group spent significantly more time in-range (P < 0.001), had a control group whose INRs were significantly lower than expected.

Note

Date of latest search:

    References

    • Garcia P, Ruiz W, Loza Munárriz C. Warfarin initiation nomograms for venous thromboembolism. Cochrane Database Syst Rev 2016;(1):CD007699. [PubMed].
    • Mahtani KR, Heneghan CJ, Nunan D et al. Optimal loading dose of warfarin for the initiation of oral anticoagulation. Cochrane Database Syst Rev 2012;(12):CD008685. [PubMed]

Primary/Secondary Keywords